| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ALL ISSUES | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
REGULAR ARTICLE |
Section of Geriatric Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, and the Baltimore Veterans Affairs Medical Center, Baltimore, Maryland.
The authors examined the efficacy of naltrexone as an adjunctive treatment for alcohol dependence in older adults. Forty-four veterans over 50 years of age were enrolled in a 12-week, double-blind, placebo-controlled efficacy study of naltrexone (the equivalent of 50 nig per day). There were no differences in the frequency of any self-reported adverse effects or in liver enzyme values between the placebo- and naltrexone-treated groups. There were no differences between the treatment groups in the number of subjects remaining abstinent or in the number of subjects who relapsed. However; all placebo-treated subjects relapsed after sampling alcohol, whereas only three of six naltrexone-treated subjects met relapse criteria after alcohol exposure (P = 0.024). The authors conclude that naltrexone was well tolerated and efficacious in preventing relapse in subjects who drank.
This article has been cited by other articles:
|
|
 |
|
  S. Rosner, S. Leucht, P. Lehert, and M. Soyka Acamprosate supports abstinence, Naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes J Psychopharmacol, January 1, 2008; 22(1): 11 - 23. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Zanjani, S. Mavandadi, T. TenHave, I. Katz, N. B. Durai, D. Krahn, M. Llorente, J. Kirchner, E. Olsen, W. Van Stone, et al. Longitudinal Course of Substance Treatment Benefits in Older Male Veteran At-Risk Drinkers J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2008; 63(1): 98 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Steensland, J. A. Simms, J. Holgate, J. K. Richards, and S. E. Bartlett Varenicline, an {alpha}4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking PNAS, July 24, 2007; 104(30): 12518 - 12523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Oslin Treatment of Late-Life Depression Complicated by Alcohol Dependence Am J Geriatr Psychiatry, June 1, 2005; 13(6): 491 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Oslin Late-Life Alcoholism: Issues Relevant to the Geriatric Psychiatrist Am J Geriatr Psychiatry, December 1, 2004; 12(6): 571 - 583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Kiefer, H. Jahn, T. Tarnaske, H. Helwig, P. Briken, R. Holzbach, P. Kampf, R. Stracke, M. Baehr, D. Naber, et al. Comparing and Combining Naltrexone and Acamprosate in Relapse Prevention of Alcoholism: A Double-blind, Placebo-Controlled Study Arch Gen Psychiatry, January 1, 2003; 60(1): 92 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Oslin, H. Pettinati, and J. R. Volpicelli Alcoholism Treatment Adherence: Older Age Predicts Better Adherence and Drinking Outcomes Am J Geriatr Psychiatry, December 1, 2002; 10(6): 740 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Fuller and E. Gordis Naltrexone Treatment for Alcohol Dependence N. Engl. J. Med., December 13, 2001; 345(24): 1770 - 1771. [Full Text] [PDF]
|
|
|
|
 |
|
 H. R. Kranzler PHARMACOTHERAPY OF ALCOHOLISM: GAPS IN KNOWLEDGE AND OPPORTUNITIES FOR RESEARCH Alcohol Alcohol., November 1, 2000; 35(6): 537 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Mason, F. R. Salvato, L. D. Williams, E. C. Ritvo, and R. B. Cutler A Double-blind, Placebo-Controlled Study of Oral Nalmefene for Alcohol Dependence Arch Gen Psychiatry, August 1, 1999; 56(8): 719 - 724. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ALL ISSUES | SEARCH | TABLE OF CONTENTS |
